Natte krant schreef op 8 oktober 2015 17:02:
Bron KBC Securities
Shining the light on cystic fibrosis at US conference
Our View:
The posters will become available on Galapagos’s website following their presentation.
Friday, 9 October 7.30 AM - 8.45 AM
1. Potentiators: how do they impact the fate of CFTR during biogenesis?
Insights are presented on the contribution of GLPG1837 to the rescue of F508del CFTR...
Conclusion:
All posters deal with preclinical and laboratory data, except for one which presents the phase 1 data in healthy volunteers on its CF potentiator molecule GLPG1837 which is expected to move into phase 2 by YE15.
Given the huge interest from (specialist) investors in cystic fibrosis, we expect Galapagos to seek the spotlight at this conference to position itself as the competitor for Vertex in the race to the triple CF combo therapy (expected to enter phase 2 in 2017.